Research programme: bone marrow stem cell therapy - neurological disorders - SanBio

Drug Profile

Research programme: bone marrow stem cell therapy - neurological disorders - SanBio

Alternative Names: SB 308; SB 618

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SanBio
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Multiple sclerosis; Muscular dystrophies; Spinal cord injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (Intrathecal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top